Morgan Stanley cuts Clorox stock price target on sales struggles By Investing.com

Morgan Stanley cut Clorox’s price target to $97 from $110 and kept an Equalweight rating, citing persistent sales weakness in litter and salad dressing plus rising cost pressure with limited pricing offsets. Clorox also trimmed FY2026 adjusted EPS guidance to $5.45-$5.65 from $5.95-$6.30, even after Q3 EPS of $1.64 beat the $1.55 consensus on revenue of $1.67 billion in line with expectations. Goldman Sachs and Evercore ISI also lowered targets, reinforcing a cautious outlook on margins and share trends.

Analysis

This is less a single-quarter miss than a credibility event: when multiple sell-side shops converge on lower targets while management is still digesting ERP and acquisition integration, the market starts discounting a longer earnings reset rather than a cyclical wobble. The important second-order effect is that weak brands with limited pricing power become trapped between inflation and volume loss, forcing either heavier promo spend or a multi-year share defense strategy; both paths compress ROIC before they show up in reported EPS.

For staples peers, the read-through is not just sector multiple compression but a possible re-rating wedge between manufacturers with true mix/pricing leverage and those dependent on household replenishment categories. If CLX is forced into more aggressive reinvestment in the next fiscal year, retailers may gain bargaining leverage across adjacent categories, which can spill into private label share gains and pressure smaller branded peers with less scale to absorb SG&A inefficiency.

The catalyst path is asymmetric: near term, the stock can stay weak as estimate cuts flow through over the next 1-2 earnings cycles; medium term, any stabilization in scan data or evidence that reinvestment is arresting share loss could trigger a sharp relief rally because positioning is likely already defensive. The tail risk is that margin pressure and execution issues overlap, turning a guidance reset into a multi-quarter de-rating, especially if management cannot demonstrate that the ERP drag is temporary rather than structural.

Consensus may be missing that the market may be underestimating how much of the downside is already in the stock versus how long it takes for fundamentals to normalize. That argues for expressing the view with defined risk rather than outright panic selling: the earnings quality is deteriorating, but the valuation is now close enough to a distress-style floor that incremental bad news matters more than the current level of bad news.

Key Decisions for Investors

• Maintain a tactical short CLX into the next 1-2 earnings windows; use a tight stop above the prior analyst consensus zone, because the setup favors continued estimate cuts but the stock is close enough to multi-year support that upside squeeze risk is real.
• Prefer a put spread over outright short CLX: buy 3-6 month puts and finance with a lower-strike sale to capture a further 8-15% downside if guidance is cut again, while limiting theta decay if the stock grinds sideways.
• Pair trade: long higher-quality staples with better pricing power, short CLX for 2-3 months. The trade is a relative-margin bet that should work if the market keeps rewarding companies with cleaner reinvestment levers and penalizing execution drag.
• If looking for a reversal, wait for proof of scan-data stabilization or retailer order normalization before going long; any long should be small and only on confirmation, since the first rally after a reset can be a bear-market bounce.
• Avoid chasing GS/EVR downside from this print; the more actionable expression is in CLX itself, with the downstream read-through to staples sentiment already largely absorbed by the group.